Potassium chloride

Identification

Summary

Potassium chloride is a potassium salt used to treat hypokalemia.

Brand Names

Bi-peglyte, Bss, Bss Ophthalmic Solution, Cardioplegic, Citrasate, Colyte, Dextrose and Electrolyte No. 75, Diphen, Eye Stream, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Glycerolyte 57, Golytely, H.E.L.P.bicel, Hemosate Ultra, Ionosol-MB, Isolyte P, Isolyte S, Isolyte S pH 7.4, Isoplate, K 45, K-tab, Klor-con, Lactated Ringers, Moviprep, Naturalyte, Normosol-R, Nulytely, Nxstage Pureflow, Olimel, Peglyte, Periolimel, Phoxillum, Physiolyte, Physiosol, Plasma-lyte, Plasma-lyte 148, Plasma-lyte 148 In 5 % Dextrose, Plasma-lyte R, Plasmalyte A, Plegisol, Plenvu, Prismasol, Procalamine 3, Ringers, Selectbag One, Tis-U-sol

Generic Name

Potassium chloride

DrugBank Accession Number

DB00761

Background

A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives.

Type

Small Molecule

Groups

Approved, Withdrawn

Structure

Download

MOLSDFPDBSMILESInChI

Similar Structures

Structure for Potassium chloride (DB00761)

×

Close

Weight

Average: 74.551
Monoisotopic: 73.932559568

Chemical Formula

ClK

Synonyms

• Chlorid draselny
• Chloride of potash
• Kaliumchlorid
• KCl
• Monopotassium chloride
• Muriate of potash
• Potassium chloride
• Sylvite

External IDs

• B1653
• E 508
• E-508
• INS NO.508
• INS-508
• NSC-77368

Pharmacology

Indication

For use as an electrolyte replenisher and in the treatment of hypokalemia.

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

• Dehydration
• Dry Mouth
• Hypokalemia
• Hypotonic Dehydration
• Hypovolaemia
• Isotonic Dehydration
• Markedly Reduced Food Intake
• Metabolic Acidosis
• Hypodermoclysis
• Mild Metabolic acidosis
• Mild, moderate Metabolic Acidosis
• Ocular edema

Associated Therapies

• Acid- Base Balance
• Bowel preparation therapy
• Electrolyte replacement
• Fluid replacement therapy
• Haemofiltration
• Hemodialysis Treatment
• Parenteral Nutrition
• Parenteral rehydration therapy
• Plasma Volume Replacement
• Urine alkalinization therapy
• Fluid and electrolyte maintenance therapy

Contraindications & Blackbox Warnings

Avoid life-threatening adverse drug events

Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events & improve clinical decision support.

Learn more

Pharmacodynamics

The potassium ion is in the principle intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle, and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops as a consequence of therapy with diuretics, primarily or secondary hyperaldosteronism, diabetic ketoacidosis, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Depletion can develop rapidly with severe diarrhea, especially if associated with vomiting. Potassium depletion due to these causes is usually accompanied by concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness, fatigue, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and, in advanced cases, flaccid paralysis and/or impaired ability to concentrate urine. If potassium depletion associated with metabolic alkalosis cannot be managed by correcting the fundamental cause of the deficiency, e.g., where the patient requires long-term diuretic therapy, supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels. In rare circumstances (e.g., patients with renal tubular acidosis) potassium depletion may be associated with metabolic acidosis and hyperchloremia. In such patients, potassium replacement should be accomplished with potassium salts other than the chloride, such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.

Mechanism of action

Supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels.

Target	Actions	Organism
USolute carrier family 12 member 2	Not Available	Humans
USolute carrier family 12 member 1	binder	Humans
USolute carrier family 12 member 5	Not Available	Humans
USolute carrier family 12 member 6	Not Available	Humans
USolute carrier family 12 member 7	Not Available	Humans
USolute carrier family 12 member 4	Not Available	Humans

Absorption

Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Potassium is a normal dietary constituent and, under steady-state conditions, the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake.

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

Learn more

Improve decision support & research outcomes with our structured adverse effects data.

Learn more

Toxicity

The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, of if potassium is administered too rapidly intravenously, potentially fatal hyperkalemia can result. It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5-8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-wave, depression of S-T segment, and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9-12 mEq/L).

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Abacavir	Potassium chloride may decrease the excretion rate of Abacavir which could result in a higher serum level.
Acebutolol	Potassium chloride may increase the hyperkalemic activities of Acebutolol.
Aceclofenac	Potassium chloride may increase the hyperkalemic activities of Aceclofenac.
Acemetacin	Potassium chloride may increase the hyperkalemic activities of Acemetacin.
Acetaminophen	Acetaminophen may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
Acetazolamide	Acetazolamide may increase the excretion rate of Potassium chloride which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acid	Potassium chloride may increase the hyperkalemic activities of Acetylsalicylic acid.
Aclidinium	The risk or severity of gastrointestinal ulceration can be increased when Aclidinium is combined with Potassium chloride.
Acrivastine	Potassium chloride may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Acyclovir	Acyclovir may decrease the excretion rate of Potassium chloride which could result in a higher serum level.

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Food Interactions

• Take with a full glass of water.
• Take with food. This reduces gastrointestinal irritation.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Active Moieties

Name	Kind	UNII	CAS	InChI Key
Potassium cation	ionic	295O53K152	24203-36-9	NPYPAHLBTDXSSS-UHFFFAOYSA-N
Chloride ion	ionic	Q32ZN48698	16887-00-6	VEXZGXHMUGYJMC-UHFFFAOYSA-M

Product Images

PreviousNext

International/Other Brands

Kaon Cl / Kaon-CL 10 / Micro-K / Sando-K / Slow-K

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Chlorure de potassium Proamp	Injection, solution, concentrate	0.15 g/1mL	Intravenous	Laboratoire Aguettant	2018-07-31	Not applicable
Epiklor	Powder, for solution	1.5 g/1.77g	Oral	Epic Pharma, LLC	2010-02-01	2013-10-01
Epiklor/25	Powder, for solution	1.875 g/2.21g	Oral	Epic Pharma, LLC	2010-02-01	2013-09-01
HUMCO Potassium Chloride 10 Percent	Liquid	100 mg/1mL	Oral	Humco Holding Group. Inc.	1979-01-01	2015-12-31
K + 45	Liquid	251.6 g / L	Hemodialysis	Baxter Laboratories	1990-12-31	Not applicable
K C1-rougier	Liquid	750 mg / 15 mL	Oral	Rougier Pharma Division Of Ratiopharm Inc	1967-12-31	1999-09-27
K Lor Granules 20meq	Powder, for solution	1.5 g / 3 g	Oral	Abbott	1979-12-31	2008-06-06
K Lyte Cl Pwr	Powder, for solution	1.86 g / 7.8 g	Oral	Bristol Labs Division Of Bristol Myers Squibb	1965-12-31	1997-08-14
K-dur	Tablet, extended release	750 mg/1	Oral	Merck Sharp & Dohme Limited	1986-06-13	2008-10-31
K-dur	Tablet, extended release	1.5 g	Oral	Merck Ltd.	1989-12-31	2014-12-04

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Klor Con M	Tablet, extended release	1500 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	1998-11-20	Not applicable
Klor Con M	Tablet, extended release	750 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	1998-11-20	Not applicable
Klor-con	Powder, for solution	1.5 g/1	Oral	Upsher-Smith Laboratories, LLC	2017-10-23	Not applicable
Klor-Con	Tablet, extended release	1500 mg/1	Oral	Apace Packaging	2000-08-09	2014-09-30
Klor-Con M	Tablet, extended release	750 mg/1	Oral	Cardinal Health	2011-01-18	2012-10-31
Klor-con M	Tablet, extended release	1500 mg/1	Oral	Cardinal Health	2014-09-01	2021-05-31
Klor-Con M	Tablet, extended release	1125 mg/1	Oral	Med Health Pharma LLC	2011-05-10	2012-06-10
Klor-con M	Tablet, extended release	1500 mg/1	Oral	Sandoz Inc.	2011-01-18	2021-10-31
Klor-Con M	Tablet, extended release	1500 mg/1	Oral	PD-Rx Pharmaceuticals, Inc.	2011-01-18	2019-09-12
Klor-Con M	Tablet, extended release	750 mg/1	Oral	Upsher-Smith Laboratories, Inc.	2011-01-18	2015-12-31

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
ADDI-K	Tablet, extended release	750 mg	Oral	บริษัท ดีเคเอสเอช (ประเทศไทย) จำกัด	2010-05-17	Not applicable
APO-K TABLET 600 mg	Tablet, film coated	600 mg	Oral	PHARMAFORTE SINGAPORE PTE LTD	1991-08-19	Not applicable
APO-K TABLET 600MG (S/R)	Tablet		Oral	PHARMAFORTE (MALAYSIA) SDN. BHD.	2020-09-08	Not applicable
Hi Potency Potassium Chloride	Tablet, extended release	500 mg	Oral	Swiss Herbal Remedies Ltd.	1997-02-24	2001-08-02
Kaochlor-20	Solution	3 g / 15 mL	Oral	Pfizer Canada Ulc	1995-12-31	2006-08-02
Micro-K-10 Extencaps Src 750mg	Capsule, extended release	750 mg / src	Oral	Wyeth Ayerst Canada Inc.	1994-12-31	2003-07-28
POTASSIUM CHLORIDE INJECTION - HIGHLY CONCENTRATED (100 mEq/l)	Injection	746 mg/100ml	Intravenous	BAXTER HEALTHCARE (ASIA) PTE LTD	2001-05-29	Not applicable
POTASSIUM CHLORIDE INJECTION - HIGHLY CONCENTRATED (200 mEq/l)	Injection	746 mg/50ml	Intravenous	BAXTER HEALTHCARE (ASIA) PTE LTD	2001-06-21	Not applicable
POTASSIUM CHLORIDE INJECTION - HIGHLY CONCENTRATED (400 mEq/l)	Injection	1.49 g/50ml	Intravenous	BAXTER HEALTHCARE (ASIA) PTE LTD	2001-06-21	Not applicable
POTASSIUM CHLORIDE MIXTURE 500 mg/5 ml	Solution	500 mg/5ml	Oral	BEACONS PHARMACEUTICALS PTE. LTD.	1995-11-11	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
(20 Mmol/l) Potassium Chloride In 3.3% Dextrose and 0.3% Sodium Chloride Injection USP	Potassium chloride (150 mg / 100 mL) + Dextrose, unspecified form (3.3 g / 100 mL) + Sodium chloride (300 mg / 100 mL)	Solution	Intravenous	Baxter Laboratories	1978-12-31	Not applicable
(20 Mmol/l) Potassium Chloride In 5% Dextrose and 0.9% Sodium Chloride Injection USP	Potassium chloride (150 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL) + Sodium chloride (900 mg / 100 mL)	Solution	Intravenous	Baxter Laboratories	1990-12-31	Not applicable
(20 Mmol/l) Potassium Chloride In 5% Dextrose Injection USP	Potassium chloride (150 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL)	Solution	Intravenous	Baxter Laboratories	1989-12-31	Not applicable
(20mmol/l) Potassium Chloride In 0.9% Sodium Chloride Injection USP	Potassium chloride (150 mg / 100 mL) + Sodium chloride (900 mg / 100 mL)	Solution	Intravenous	Baxter Laboratories	1989-12-31	Not applicable
(20mmol/l) Potassium Chloride In 5% Dextrose and 0.2% Sodium Chloride Injection USP	Potassium chloride (150 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL) + Sodium chloride (200 mg / 100 mL)	Solution	Intravenous	Baxter Laboratories	1989-12-31	2016-07-15
(20mmol/l) Potassium Chloride In 5% Dextrose and 0.45% Sodium Chloride Injection USP	Potassium chloride (150 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL) + Sodium chloride (450 mg / 100 mL)	Solution	Intravenous	Baxter Laboratories	1989-12-31	Not applicable
(40 Mmol/l) Potassium Chloride In 0.9% Sodium Chloride Injection USP	Potassium chloride (300 mg / 100 mL) + Sodium chloride (900 mg / 100 mL)	Liquid	Intravenous	Baxter Laboratories	1989-12-31	Not applicable
(40 Mmol/l) Potassium Chloride In 5% Dextrose Injection USP	Potassium chloride (300 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL)	Solution	Intravenous	Baxter Laboratories	1989-12-31	Not applicable
(40 Mmols/l) Potassium Chloride In Lactated Ringer's Injection USP	Potassium chloride (328 mg / 100 mL) + Calcium chloride (20 mg / 100 mL) + Sodium lactate (310 mg / 100 mL) + Sodium chloride (600 mg / 100 mL)	Solution	Intravenous	Baxter Laboratories	2002-12-11	2016-07-15
(40mmol/l) Potassium Chloride In 3.3% Dextrose and 0.3% Sodium Chloride Injection USP	Potassium chloride (300 mg / 100 mL) + Dextrose, unspecified form (3.3 g / 100 mL) + Sodium chloride (300 mg / 100 mL)	Solution	Intravenous	Baxter Laboratories	1978-12-31	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
BIOFLEKS %5 DEKSTROZ RINGER LAKTAT 500 ML SOLUSYON (PVC TORBA) SETSIZ	Potassium chloride (0.03 %) + Calcium chloride (0.02 %) + Dextrose, unspecified form (5 %) + Sodium lactate (0.31 %) + Sodium chloride (0.6 %)	Solution	Intravenous	OSEL İLAÇ SAN. VE TİC. A.Ş.	2020-08-14	Not applicable
BIOFLEKS %5 DEKSTROZ RINGER LAKTAT ENJEKTABL SOL (PVC TORBA) 1000 ML SETLI	Potassium chloride (0.03 %) + Calcium chloride (0.02 %) + Dextrose, unspecified form (5 %) + Sodium lactate (0.31 %) + Sodium chloride (0.6 %)	Solution	Intravenous	OSEL İLAÇ SAN. VE TİC. A.Ş.	2020-08-14	Not applicable
BIOFLEKS %5 DEKSTROZ RINGER LAKTAT ENJEKTABL SOL (PVC TORBA) 1000 ML SETSIZ	Potassium chloride (0.03 %) + Calcium chloride (0.02 %) + Dextrose, unspecified form (5 %) + Sodium lactate (0.31 %) + Sodium chloride (0.6 %)	Solution	Intravenous	OSEL İLAÇ SAN. VE TİC. A.Ş.	2020-08-14	Not applicable
BIOFLEKS %5 DEKSTROZ RINGER LAKTAT ENJEKTABL SOL (PVC TORBA) 500 ML SETLI	Potassium chloride (0.03 %) + Calcium chloride (0.02 %) + Dextrose, unspecified form (5 %) + Sodium lactate (0.31 %) + Sodium chloride (0.6 %)	Solution	Intravenous	OSEL İLAÇ SAN. VE TİC. A.Ş.	2020-08-14	Not applicable
BIOFLEKS 10 MEQ/L POTASYUM KLORUR %5 DEKSTROZ SOLUSYONU 1000 ML SETLI	Potassium chloride (10 mEq/L) + D-glucose monohydrate (5 %)	Solution	Intravenous	OSEL İLAÇ SAN. VE TİC. A.Ş.	2020-08-14	Not applicable
BIOFLEKS 10 MEQ/L POTASYUM KLORUR %5 DEKSTROZ SOLUSYONU 1000 ML SETSIZ	Potassium chloride (10 mEq/L) + D-glucose monohydrate (5 %)	Solution	Intravenous	OSEL İLAÇ SAN. VE TİC. A.Ş.	2020-08-14	Not applicable
BIOFLEKS 10 MEQ/L POTASYUM KLORUR %5 DEKSTROZ SOLUSYONU 500 ML SETLI	Potassium chloride (10 mEq/L) + D-glucose monohydrate (5 %)	Solution	Intravenous	OSEL İLAÇ SAN. VE TİC. A.Ş.	2020-08-14	Not applicable
BIOFLEKS 10 MEQ/L POTASYUM KLORUR %5 DEKSTROZ SOLUSYONU 500 ML SETSIZ	Potassium chloride (10 mEq/L) + D-glucose monohydrate (5 %)	Solution	Intravenous	OSEL İLAÇ SAN. VE TİC. A.Ş.	2020-08-14	Not applicable
BIOFLEKS 20MEQ/L KCL%5DEK 100 ML SOLUSYON SETSIZ	Potassium chloride (20 mEq/L) + D-glucose monohydrate (5 %)	Solution	Intravenous	OSEL İLAÇ SAN. VE TİC. A.Ş.	2020-08-14	Not applicable
BIOFLEKS 20MEQ/L KCL%5DEK 1000 ML SOLUSYON SETSIZ	Potassium chloride (20 mEq/L) + D-glucose monohydrate (5 %)	Solution	Intravenous	OSEL İLAÇ SAN. VE TİC. A.Ş.	2020-08-14	Not applicable

Categories

ATC Codes

A12BA51 — Potassium chloride, combinations

• A12BA — Potassium
• A12B — POTASSIUM
• A12 — MINERAL SUPPLEMENTS
• A — ALIMENTARY TRACT AND METABOLISM

B05XA01 — Potassium chloride

• B05XA — Electrolyte solutions
• B05X — I.V. SOLUTION ADDITIVES
• B05 — BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
• B — BLOOD AND BLOOD FORMING ORGANS

A12BA01 — Potassium chloride

• A12BA — Potassium
• A12B — POTASSIUM
• A12 — MINERAL SUPPLEMENTS
• A — ALIMENTARY TRACT AND METABOLISM

Drug Categories

• Agents causing hyperkalemia
• Alimentary Tract and Metabolism
• Blood and Blood Forming Organs
• Blood Substitutes and Perfusion Solutions
• Chlorides
• Chlorine Compounds
• Drugs that are Mainly Renally Excreted
• Electrolyte Solutions
• Hemodialysis Solution
• I.V. Solution Additives
• Mineral Supplements
• Minerals
• Potassium Compounds
• Potassium Salt
• Replacement Preparations

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of inorganic compounds known as alkali metal chlorides. These are inorganic compounds in which the largest halogen atom is Chlorine, and the heaviest metal atom is an alkali metal.

Kingdom

Inorganic compounds

Super Class

Mixed metal/non-metal compounds

Class

Alkali metal salts

Sub Class

Alkali metal chlorides

Direct Parent

Alkali metal chlorides

Alternative Parents

Inorganic chloride salts

Substituents

Alkali metal chloride / Inorganic chloride salt / Inorganic salt

Molecular Framework

Not Available

External Descriptors

potassium salt, inorganic chloride (CHEBI:32588)

Affected organisms

• Humans and other mammals

Chemical Identifiers

UNII

660YQ98I10

CAS number

7447-40-7

InChI Key

WCUXLLCKKVVCTQ-UHFFFAOYSA-M

InChI

InChI=1S/ClH.K/h1H;/q;+1/p-1

IUPAC Name

potassium chloride

SMILES

[Cl-].[K+]

References

Synthesis Reference

Fritz Hagedorn, Gerd Peuschel, Arno Singewald, "Method for the production of potassium chloride with K.sub.2 O content of more than 55 weight percent." U.S. Patent US5057208, issued July, 1955.

US5057208

General References

Not Available

External Links

KEGG Drug

D02060

PubChem Compound

4873

PubChem Substance

46506038

ChemSpider

4707

RxNav

8591

ChEBI

32588

ChEMBL

CHEMBL1200731

Therapeutic Targets Database

DAP000828

PharmGKB

PA451055

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

Wikipedia

Potassium_chloride

FDA label

Download (632 KB)

MSDS

Download (72.6 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Not Available	Colonoscopy	1
4	Completed	Basic Science	Blood Pressures / High Blood Pressure (Hypertension)	1
4	Completed	Basic Science	Constipation - Functional / Irritable Bowel Syndrome Characterized by Constipation	1
4	Completed	Diagnostic	Colon Adenomas / Colon Lesions / Colon Polyps	1
4	Completed	Screening	Colorectal Cancer	1
4	Completed	Supportive Care	Colorectal Cancer	1
4	Completed	Treatment	Arrhythmia / Hypokalemia	1
4	Completed	Treatment	Atrial Fibrillation / Atrial Flutter	1
4	Completed	Treatment	Bowel Preparation for Colonoscopy	1
4	Completed	Treatment	Cesarean Sections / Hypotension / Pregnancy / Spinal Anesthesia therapy	1

Pharmacoeconomics

Manufacturers

• Novo nordisk inc
• Savage laboratories inc div altana inc
• Kv pharmaceutical co
• Teva pharmaceuticals usa inc
• Watson laboratories inc florida
• Abraxis pharmaceutical products
• Akorn inc
• App pharmaceuticals llc
• B braun medical inc
• Baxter healthcare corp anesthesia and critical care
• Baxter healthcare corp
• Gd searle llc
• Hospira inc
• International medication system
• Eli lilly and co
• Luitpold pharmaceuticals inc
• Miles laboratories inc
• Pharma serve inc sub torigian laboratories
• Watson laboratories inc
• Future pak ltd
• Upsher smith laboratories inc
• Apothecon inc div bristol myers squibb
• Abbott laboratories pharmaceutical products div
• Copley pharmaceutical inc
• Eurand america inc
• Schering corp
• Novartis pharmaceuticals corp
• Upsher-Smith Laboratories Inc.

Packagers

• Abbott Laboratories Ltd.
• Actavis Group
• Advanced Pharmaceutical Services Inc.
• Alaven Pharmaceutical
• Amerisource Health Services Corp.
• Amneal Pharmaceuticals
• Apace Packaging
• Apothecon
• APP Pharmaceuticals
• A-S Medication Solutions LLC
• B. Braun Melsungen AG
• Baxter International Inc.
• Bristol-Myers Squibb Co.
• Bryant Ranch Prepack
• Cardinal Health
• Caremark LLC
• Century Pharmaceuticals Inc.
• Chemrich Laboratories Inc.
• Comprehensive Consultant Services Inc.
• Corvit Pharmaceuticals
• Coupler Enterprises Inc.
• Dept Health Central Pharmacy
• DHHS Program Support Center Supply Service Center
• Direct Dispensing Inc.
• Dispensing Solutions
• Diversified Healthcare Services Inc.
• Edwards Pharmaceuticals
• Epic Pharma LLC
• Ethex Corp.
• Eurand Pharmaceuticals Inc.
• Forest Pharmaceuticals
• General Injectables and Vaccines Inc.
• H and H Laboratories
• H.J. Harkins Co. Inc.
• Heartland Repack Services LLC
• Hospira Inc.
• Humco
• John Ross Chemical Ltd.
• Kaiser Foundation Hospital
• KV Pharmaceutical Co.
• Laboratoires Upsa
• Lake Erie Medical and Surgical Supply
• Legacy Pharmaceuticals Packaging LLC
• Liberty Pharmaceuticals
• Major Pharmaceuticals
• Mallinckrodt Inc.
• Mckesson Corp.
• Mead Johnson and Co.
• Murfreesboro Pharmaceutical Nursing Supply
• Mylan
• Neighborcare Repackaging Inc.
• Neuman Distributors Inc.
• Novartis AG
• Nucare Pharmaceuticals Inc.
• Palmetto Pharmaceuticals Inc.
• Par Pharmaceuticals
• PCA LLC
• PD-Rx Pharmaceuticals Inc.
• Pharmaceutical Association
• Pharmaceutical Packaging Center
• Pharmaceutical Utilization Management Program VA Inc.
• Pharmacia Inc.
• Pharmedix
• Physicians Total Care Inc.
• Preferred Pharmaceuticals Inc.
• Prepackage Specialists
• Prepak Systems Inc.
• Prescript Pharmaceuticals
• Qualitest
• Rebel Distributors Corp.
• Remedy Repack
• Sandhills Packaging Inc.
• Sandoz
• Savage Labs
• Schering Corp.
• Schering-Plough Inc.
• Southwood Pharmaceuticals
• Summit Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• Ther-Rx Corp.
• Tower Laboratories Ltd.
• Tya Pharmaceuticals
• United Research Laboratories Inc.
• Upsher Smith Laboratories
• Va Cmop Dallas
• Vangard Labs Inc.
• Vintage Pharmaceuticals Inc.
• Warrick Pharmaceuticals Corp.
• Watson Pharmaceuticals
• Wockhardt Ltd.

Dosage Forms

Form	Route	Strength
Liquid	Intravenous
Injection	Intravenous	50 g/L
Solution	Hemodialysis	0.257 g/1000ml
Tablet, extended release	Oral	750 mg
Solution	Irrigation; Parenteral
Powder, for solution	Intraocular
Solution	Intraocular
Tablet, film coated	Oral	600 mg
Solution	Ophthalmic
Kit; powder, for solution; tablet, delayed release	Oral
Powder, for solution	Oral	1.685 g
Solution	Hemodialysis; Intravenous
Solution	Hemodialysis; Intravenous	0.187 g/L
Concentrate; kit; solution	Ophthalmic
Kit; solution	Intraocular
Solution	Intra-arterial
Injection, solution, concentrate	Intravenous	0.15 g/1mL
Solution	Intravenous	1.49 g
Solution	Parenteral	0.149 g
Solution	Parenteral	1.49 g
Solution	Intravenous	20 mEq/mL
Solution	Intravenous	10 g
Solution	Intravenous	1.491 g
Powder, for solution	Nasogastric
Solution	Intravenous	0.27 g/1000ml
Injection	Intravenous	0.027 g/100ml
Injection	Intravenous	270 mg/l
Solution	Irrigation
Injection	Other
Injection	Other	16 mmol/20ml
Injection	Intravenous
Cream; kit; liquid; ointment; tablet; tablet, chewable; tablet, film coated	Oral; Topical
Solution	Ophthalmic	0.02 %
Solution	Intravenous	4.21 g/1000ml
Tablet, effervescent	Oral
Granule, for solution	Oral
Solution	Intrathecal
Injection	Intrathecal
Solution	Intravenous; Subcutaneous
Powder	Oral
Powder, for solution	Oral	1.5 g/1.77g
Powder, for solution	Oral	1.875 g/2.21g
Granule, for solution	Oral	64 g
Solution, concentrate	Hemodialysis
Solution	Intravenous	0.15 g/1000ml
Spray	Oral
Aerosol, spray	Oral
Solution	Other	57 g/100ml
Solution	Unknown
Solution	Extracorporeal
Powder, for solution	Nasogastric; Oral
Solution	Hemodialysis
Solution	Hemodialysis	7.77 g/l
Solution	Hemodialysis	6.47 g/l
Solution	Hemodialysis	8.46 g/l
Solution	Hemodialysis	8.8 g/l
Solution	Hemodialysis	8.85 g/l
Solution	Hemodialysis	9.74 g/l
Liquid	Hemodialysis
Solution	Hemodialysis	6.77 g/l
Tablet, extended release	Oral	500 mg
Solution	Oral	0.2892 g
Solution	Oral
Solution	Conjunctival; Ophthalmic
Liquid	Oral	100 mg/1mL
Patch	Topical
Solution, concentrate	Intravenous	100 mmol/L
Solution, concentrate	Intravenous	200 mmol/L
Solution, concentrate	Intravenous	400 mmol/L
Injection	Parenteral	746 mg
Injection	Parenteral	2.24 g
Injection	Parenteral	2.98 g
Injection	Parenteral
Liquid	Intraocular
Solution	Intravenous
Liquid	Hemodialysis	251.6 g / L
Liquid	Oral	750 mg / 15 mL
Powder, for solution	Oral	1.5 g / 3 g
Injection	Parenteral	1.49 g
Tablet, extended release	Oral	1.5 g
Elixir	Oral	10 g
Powder, for solution	Oral	1.86 g / 7.8 g
Tablet	Oral	900 mg
Liquid	Oral	20 meq/15mL
Liquid	Oral	40 meq/15mL
Tablet, film coated, extended release	Oral	1500 mg/1
Tablet, film coated, extended release	Oral	750 mg/1
Solution	Intravenous	74.5 mg
Injection, emulsion	Intravenous
Injection	Intravenous	2.3 g/1000ml
Injection	Intravenous	1.6 g/l
Capsule, extended release	Oral	600 mg
Tablet, extended release	Oral	750 mg / tab
Solution	Intravenous	1.491 g/20ml
Injection, solution, concentrate	Intravenous	74.5 mg/ml
Injection, solution, concentrate	Intravenous	15 %
Solution	Oral	10 %
Solution	Oral	3 g / 15 mL
Powder, for solution	Oral	1.5 g / pck
Tablet, sugar coated	Oral	600 mg
Solution	Oral	200 mg / mL
Powder, for solution	Oral	1.875 g/1
Powder, for solution	Oral	20 meq/1
Tablet, extended release	Oral	750 mg/1
Tablet, extended release	Oral	10 meq/1
Tablet, extended release	Oral	1125 mg/1
Tablet, extended release	Oral	20 meq/1
Tablet, film coated, extended release	Oral
Injection	Intravenous	20 mg/100ml
Solution, for slush	Irrigation
Injection	Intravenous	0.027 % w/v
Solution	Intravenous
Capsule	Oral
Powder, for solution	Oral	289.99 mg
Emulsion	Topical
Capsule, delayed release	Oral	600 mg
Capsule, extended release	Oral	600 mg / cap
Capsule, extended release	Oral	750 mg/1
Capsule, extended release	Oral	600 mg/1
Capsule, extended release	Oral	750 mg / src
Liquid	Buccal
Spray	Buccal
Powder, for solution	Oral	13.125 g
Powder, for solution	Oral	13.125 G
Injection, solution, concentrate	Oral
Kit	Oral
Injection, solution	Hemodialysis; Intravenous
Kit; solution	Intraocular; Irrigation
Granule, effervescent	Oral
Tablet, extended release	Oral	600 mg
Injection, emulsion; injection, solution	Intravenous
Injection, solution, concentrate	Intravenous
Emulsion	Intravenous	0.3 g/l
Emulsion	Intravenous
Emulsion	Intravenous	4 g
Solution, concentrate	Oral
Solution	Intraocular; Ophthalmic
Solution	Intraocular; Irrigation
Solution	Extracorporeal; Intrabiliary; Intracardiac
Injection	Intravenous
Kit; solution	Oral
Powder	Oral	238.33 g
Liquid	Oral
Emulsion	Intravenous	3 g
Irrigant	Irrigation
Injection, solution	Intravenous
Injection	Intravenous	30 mg/100ml
Injection, solution	Intra-arterial
Solution
Kit; powder, for solution	Oral
Powder, for solution	Oral
Injection, solution	Intravenous
Injection, solution	Parenteral
Solution	Oral
Solution	Parenteral
Injection, solution, concentrate	Intravenous
Injection, solution, concentrate	Intravenous	3 MEQ/ML
Capsule	Oral	750 mg/1
Capsule, coated, extended release	Oral	10 meq/1
Capsule, coated, extended release	Oral	8 meq/1
Capsule, extended release	Oral	10 meq/1
Capsule, extended release	Oral	8 meq/1
For solution	Oral	1.5 g/1.58g
For solution	Oral	1.5 g/1.54g
Injection
Injection	Intravenous	10 meq/100mL
Injection	Intravenous	10 meq/50mL
Injection	Intravenous	14.9 mg/1mL
Injection	Intravenous	150 g/1000mL
Injection	Intravenous	20 meq/50mL
Injection	Intravenous	20 meq/100mL
Injection	Intravenous	29.8 mg/1mL
Injection	Intravenous	40 meq/100mL
Injection	Intravenous	7.45 mg/1mL
Injection, solution	Intravenous	10 meq/100mL
Injection, solution	Intravenous	14.9 g/1000mL
Injection, solution	Intravenous	200 meq/1000mL
Injection, solution	Intravenous	22.4 g/1000mL
Injection, solution	Intravenous	29.8 g/1000mL
Injection, solution	Intravenous	30 meq/100mL
Injection, solution	Intravenous	400 meq/1000mL
Injection, solution	Intravenous	7.46 g/1000mL
Injection, solution, concentrate	Intravenous	149 mg/1mL
Injection, solution, concentrate	Intravenous	2 meq/1mL
Injection, solution, concentrate	Parenteral	14.9 g/100mL
Liquid	Oral	40 meq/30mL
Powder	Oral	20 meq/1.5g
Powder, for solution	Oral	1.5 g/1.74g
Powder, for solution	Oral	1.5 g/1
Powder, for solution	Oral	25 meq/1
Solution	Oral	1.3 meq/1mL
Solution	Oral	1.5 g/15mL
Solution	Oral	2.6 meq/1mL
Solution	Oral	20 meq/15mL
Solution	Oral	3 g/15mL
Solution	Oral	40 meq/15mL
Tablet	Oral	10 meq/1
Tablet	Oral	1125 mg/1
Tablet	Oral	1500 mg/1
Tablet	Oral	750 mg/1
Tablet, extended release	Oral	1500 mg/1
Tablet, extended release	Oral	8 meq/1
Tablet, film coated, extended release	Oral	10 meq/1
Tablet, film coated, extended release	Oral	600 mg/1
Tablet, film coated, extended release	Oral	8 meq/1
Solution	Intravenous	50 g/1000ml
Solution	Intravenous	50.0 g/1000ml
Solution	Intravenous	1.5 g/1000ml
Solution	Intravenous	3.00 g/1000ml
Powder	Hemodialysis	12.5 g / vial
Powder	Hemodialysis	13 g / vial
Powder	Hemodialysis	15.26 g / vial
Powder	Hemodialysis	25 g / vial
Powder	Hemodialysis	7.65 g / vial
Tablet	Oral	20 meq/1
Capsule	Oral	600 mg/1
Powder, for solution	Hemodialysis	7.55 g / vial
Solution	Intravenous	20 mEq / 10 mL
Solution	Intravenous	200 mEq / 100 mL
Solution	Intravenous	149 mg / mL
Solution	Intravenous	2 mEq / mL
Powder, for solution	Oral	1.5 g/1.58g
Liquid	Intravenous	2 mEq / mL
Solution	Intravenous	1.784 mg / mL
Solution	Intravenous	2.384 mg / mL
Liquid	Intravenous	149 mg / mL
Liquid	Intravenous	22.4 mg / mL
Solution	Intravenous	10 mEq / 100 mL
Solution	Intravenous	20 mEq / 100 mL
Solution	Intravenous	250 mg/1ml
Solution	Intravenous	40 mEq / 100 mL
Injection	Intravenous	746 mg/100ml
Injection	Intravenous	746 mg/50ml
Injection	Intravenous	1.49 g/50ml
Solution	Oral	500 mg/5ml
Tablet	Oral	600 mg
Tablet, extended release	Oral	600 mg / tab
Powder	Hemodialysis	6.2 g / pck
Solution	Oral	40 meq/30mL
Tablet	Oral
Kit	Hemodialysis
Injection	Intravenous	0.21 g/100ml
Douche	Vaginal
Solution	Intravenous	0.1 g/500ml
Solution	Irrigation; Topical
Injection	Intravenous	0.33 g/1L
Injection, solution	Irrigation
Liquid	Oral	10 %
Solution	Buccal; Oral; Topical
Aerosol	Oral
Granule
Tablet, extended release	Oral	600 mg/1
Injection, emulsion	Intravenous	14 g/1000ml
Injection, emulsion	Intravenous	0.28 g/1000ml
Injection, solution	Parenteral
Powder, for solution	Oral	2.9 g
Concentrate	Intravenous drip
Injection	Intravenous	7.45 g/100ml
Solution	Parenteral
Solution	Intravenous	0.3675 g/1000ml
Liquid	Intravenous	150 mg / mL
Emulsion	Intravenous	0.74 g/L
Emulsion	Parenteral
Capsule	Oral
Tablet	Oral
Liquid	Irrigation
Solution	Intravenous; Irrigation
Solution	Intravenous	0.3 g
Tablet	Oral	500 mg
Liquid	Ophthalmic
Syrup		500 mg/5ml
Solution	Intravenous	150 mg/1ml
Tablet, delayed release	Oral	500 mg
Elixir	Oral	500 mg/5ml

Prices

Unit description	Cost	Unit
Klor-Con 100 20meq Packets Box	106.77USD	box
Kay Ciel 30 20meq Packets Box	58.99USD	box
Rum-K-SF 15% Liquid 473ml Bottle	45.98USD	bottle
Klor-Con 30 25meq Packets Box	36.99USD	box
Colyte 240 gm Solution	26.0USD	bottle
Colyte-Flavored 240 gm Solution	18.17USD	bottle
K-Lor 20meq Packets	1.92USD	packet
K-lyte tablet eff	1.43USD	tablet
K-lyte-cl 25 meq tablet eff	1.43USD	tablet
Micro-K 10meq capsule	1.41USD	capsule
Micro-K 8meq capsule	1.21USD	capsule
Potassium cl 25 meq tablet eff	0.94USD	tablet
Micro-k 10 meq extencaps	0.91USD	each
Potassium Chloride CR 10meq capsule	0.9USD	capsule
Potassium Chloride CR 8meq capsule	0.87USD	capsule
K-Tabs 10meq Controlled Release Tabs	0.68USD	tab
K-tab er 10 meq tablet	0.66USD	tablet
Kaochlor-eff 20 meq tablet	0.59USD	tablet
K-tab 10 meq tablet sa	0.58USD	tablet
K-Lyte 25 meq Effervescent Tablet	0.58USD	tablet
Klor-con m20 tablet	0.57USD	tablet
Klor-Con/EF 25meq Effervescent Tabs	0.57USD	tab
Klor-Con 8meq Controlled Release Tabs	0.56USD	tab
Klor-Con M20 20meq Controlled Release Tabs	0.55USD	tab
Potassium Chloride Crys CR 20meq Controlled Release Tabs	0.53USD	tab
Potassium cl 20 meq tablet er	0.52USD	tablet
Potassium cl 20 meq tablet sa	0.52USD	tablet
Klor-con 10 meq tablet	0.5USD	tablet
Klor-con m15 tablet	0.5USD	tablet
Klotrix 10meq Controlled Release Tabs	0.5USD	tab
Potassium cl er 20 meq tablet	0.49USD	tablet
Klor-con-ef 25 meq tablet eff	0.4USD	tablet
Micro-k 8 meq extencaps	0.34USD	each
Kaon-Cl-10 10meq Controlled Release Tabs	0.3USD	tab
Klor-con m10 tablet	0.3USD	tablet
Potassium cl er 10 meq tablet	0.3USD	tablet
Potassium cl 10 meq tablet sa	0.29USD	tablet
Potassium Chloride Crys CR 10meq Controlled Release Tabs	0.28USD	tab
Potassium Chloride CR 10meq Controlled Release Tabs	0.27USD	tab
Potassium cl er 8 meq tablet	0.26USD	tablet
Kaon-cl 10 meq tablet sa	0.23USD	tablet
Potassium cl 2 meq/ml vial	0.23USD	ml
K-Dur 20 meq Sustained-Release Tablet	0.21USD	tablet
Potassium Chloride CR 8meq Controlled Release Tabs	0.18USD	tab
Klor-con 8 meq tablet	0.16USD	tablet
Slow K 8 meq Sustained-Release Tablet	0.16USD	tablet
Micro-K Extencaps 8 meq Sustained-Release Capsule	0.1USD	capsule
Apo-K 8 meq Sustained-Release Tablet	0.09USD	tablet
Potassium Chloride 40 Meq/15ml(20%) Liquid	0.06USD	ml
Potassium Chloride 20 Meq/15ml(10%) Liquid	0.03USD	ml
Potassium chloride crystals	0.02USD	g
K-10 Oral Liquid 1.33 meq/ml Liquid	0.02USD	ml
Colyte with flavor packets	0.01USD	ml
Pms - Potassium Chloride 1.33 meq/ml Liquid	0.01USD	ml

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)	Region
US7291324	No	2007-11-06	2022-10-22
US7169381	No	2007-01-30	2024-09-01
US7658914	No	2010-02-09	2024-09-01
US7084130	No	2006-08-01	2021-11-29
US9326969	No	2016-05-03	2033-09-10
US9592252	No	2017-03-14	2032-08-11
US9707297	No	2017-07-18	2033-09-10
US8999313	No	2015-04-07	2033-09-10
US10016504	No	2018-07-10	2033-09-10
US10646512	No	2020-05-12	2032-03-25
US10792306	No	2020-10-06	2032-03-09
US10780112	No	2020-09-22	2032-03-09
US10143656	No	2018-12-04	2037-08-04
US10918723	No	2021-02-16	2033-09-10
US11033498	No	2021-06-15	2037-08-04
US11382864	No	2017-08-04	2037-08-04

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	770 °C	Not Available
water solubility	Freely soluble	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	91.5 mg/mL	ALOGPS
logP	-0.05	ALOGPS
logP	0.2	ChemAxon
logS	0.09	ALOGPS
pKa (Strongest Acidic)	3.09	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	0	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	0 Å2	ChemAxon
Rotatable Bond Count	0	ChemAxon
Refractivity	0 m3·mol-1	ChemAxon
Polarizability	1.78 Å3	ChemAxon
Number of Rings	0	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.9445
Blood Brain Barrier	+	0.975
Caco-2 permeable	+	0.6764
P-glycoprotein substrate	Non-substrate	0.9039
P-glycoprotein inhibitor I	Non-inhibitor	0.9891
P-glycoprotein inhibitor II	Non-inhibitor	0.9866
Renal organic cation transporter	Non-inhibitor	0.9219
CYP450 2C9 substrate	Non-substrate	0.8116
CYP450 2D6 substrate	Non-substrate	0.717
CYP450 3A4 substrate	Non-substrate	0.7571
CYP450 1A2 substrate	Non-inhibitor	0.7551
CYP450 2C9 inhibitor	Non-inhibitor	0.8594
CYP450 2D6 inhibitor	Non-inhibitor	0.9314
CYP450 2C19 inhibitor	Non-inhibitor	0.8365
CYP450 3A4 inhibitor	Non-inhibitor	0.9576
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9002
Ames test	Non AMES toxic	0.6808
Carcinogenicity	Carcinogens	0.7523
Biodegradation	Ready biodegradable	0.6815
Rat acute toxicity	1.9786 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9433
hERG inhibition (predictor II)	Non-inhibitor	0.9634

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Not Available

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. Solute carrier family 12 member 2

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

General Function

Sodium:potassium:chloride symporter activity

Specific Function

Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.

Gene Name

SLC12A2

Uniprot ID

P55011

Uniprot Name

Solute carrier family 12 member 2

Molecular Weight

131445.825 Da

References

1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
3. Hebert SC: Bartter syndrome. Curr Opin Nephrol Hypertens. 2003 Sep;12(5):527-32. [Article]

Details2. Solute carrier family 12 member 1

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Binder

General Function

Sodium:potassium:chloride symporter activity

Specific Function

Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.

Gene Name

SLC12A1

Uniprot ID

Q13621

Uniprot Name

Solute carrier family 12 member 1

Molecular Weight

121449.13 Da

References

1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
3. Fujiwara TM, Bichet DG: Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005 Oct;16(10):2836-46. Epub 2005 Aug 10. [Article]
4. Bichet DG: Hereditary polyuric disorders: new concepts and differential diagnosis. Semin Nephrol. 2006 May;26(3):224-33. [Article]
5. Pressler CA, Heinzinger J, Jeck N, Waldegger P, Pechmann U, Reinalter S, Konrad M, Beetz R, Seyberth HW, Waldegger S: Late-onset manifestation of antenatal Bartter syndrome as a result of residual function of the mutated renal Na+-K+-2Cl- co-transporter. J Am Soc Nephrol. 2006 Aug;17(8):2136-42. Epub 2006 Jun 28. [Article]
6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]

Details3. Solute carrier family 12 member 5

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

General Function

Protein kinase binding

Specific Function

Mediates electroneutral potassium-chloride cotransport in mature neurons. Transport occurs under isotonic conditions, but is activated 20-fold by cell swelling. Important for Cl(-) homeostasis in n...

Gene Name

SLC12A5

Uniprot ID

Q9H2X9

Uniprot Name

Solute carrier family 12 member 5

Molecular Weight

126182.49 Da

References

1. Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 (KCC2) in the Purkinje cells of embryonic mouse cerebellum. Neurosci Res. 2007 Feb;57(2):322-5. Epub 2006 Nov 28. [Article]
2. Tornberg J, Segerstrale M, Kulesskaya N, Voikar V, Taira T, Airaksinen MS: KCC2-deficient mice show reduced sensitivity to diazepam, but normal alcohol-induced motor impairment, gaboxadol-induced sedation, and neurosteroid-induced hypnosis. Neuropsychopharmacology. 2007 Apr;32(4):911-8. Epub 2006 Aug 16. [Article]
3. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
4. Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 in granule cells of the early postnatal mouse cerebellum with special reference to the synapse formation. Neuroscience. 2006 Dec;143(3):757-67. Epub 2006 Sep 27. [Article]
5. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]

Details4. Solute carrier family 12 member 6

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

General Function

Rubidium ion transmembrane transporter activity

Specific Function

Mediates electroneutral potassium-chloride cotransport. May be activated by cell swelling. May contribute to cell volume homeostasis in single cells.

Gene Name

SLC12A6

Uniprot ID

Q9UHW9

Uniprot Name

Solute carrier family 12 member 6

Molecular Weight

127615.745 Da

References

1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]
3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [Article]

Details5. Solute carrier family 12 member 7

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

General Function

Protein kinase binding

Specific Function

Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May mediate K(+) uptake into Deiters' cells in the cochlea and contribute to K(+) recycling in the inner ear....

Gene Name

SLC12A7

Uniprot ID

Q9Y666

Uniprot Name

Solute carrier family 12 member 7

Molecular Weight

119104.84 Da

References

1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]
3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [Article]

Details6. Solute carrier family 12 member 4

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

General Function

Protein kinase binding

Specific Function

Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May contribute to cell volume homeostasis in single cells. May be involved in the regulation of basolateral C...

Gene Name

SLC12A4

Uniprot ID

Q9UP95

Uniprot Name

Solute carrier family 12 member 4

Molecular Weight

120648.73 Da

References

1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]
3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [Article]

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at June 13, 2005 13:24 / Updated at September 29, 2022 07:52